A Novel RANKL-Targeted Furoquinoline Alkaloid Ameliorates Bone Loss in Ovariectomized Osteoporosis through Inhibiting the NF-κB Signal Pathway and Reducing Reactive Oxygen Species

Figure 7

DIC prevents OVX-induced bone mass loss in vivo. (a) Micro-CT images of sagittal and tibial transverse views of the knee joint in different groups of mice. (b) Trabecular bone parameter analysis of BMD, BV/TV, Tb.N, Tb.Pf, Tb.Th, and Tb.Sp. (c) H&E staining indicated that the thickness of the bone trabecula surface was more maintained in the DIC-treated groups than in the OVX group. The expression of RANKL was determined by IHC staining and compared to those in the DIC-treated and sham groups. The sections in the OVX group showed a high expression trend of RANKL in a dose-dependent manner. The activity of osteoclasts was assessed by TRAP staining. (d) Quantitative analyses of HE and TRAP staining, including BV/TV () and OcS/BS (). All bar charts are presented as the . , compared with the OVX group.

(a)

(b)

(c)

(d)